Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.51 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417389 | 0.89 | LMNA (0.62) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL14185292 | 0.86 | ALDH1A1 (0.51) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL4603757 | 0.85 | ESR1 (0.53) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL12673467 | 0.83 | SIRT2 (0.61) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL1878564 | 0.81 | RORC (0.58) | LMNAALDH1A1MAPK1NR1H3KMT2A | |
| SCHEMBL1880407 | 0.81 | ALDH1A1 (0.58) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL1880405 | 0.81 | ALDH1A1 (0.58) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL1883657 | 0.81 | KMT2A (0.55) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL6297317 | 0.80 | HSD17B1 (0.77) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL15953307 | 0.78 | SIRT2 (0.71) | LMNAHTTSMN1; SMN2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| EP-1648897-B1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INT (ES) | 2008-12-10 | — | — | EP | disclosed |
| CN-100393721-C | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INT (ES) | 2008-06-11 | — | — | CN | disclosed |
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL S.A. (ES) | 2006-11-30 | — | — | US | disclosed |
| CN-1829719-A | N- [ 3- (3-substituted-pyrazolo [1, 5-a ] pyrimidin-7-yl) phenyl ] -sulfonamides, compositions thereof, and related methods | FERRER INT (ES) | 2006-09-06 | — | — | CN | disclosed |
| EP-1648897-A1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005014597-A1 | N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | GABRA2, GABRA1, GABRA3 | LMNA 2155/4885HTT 3306/4885SMN1; SMN2 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.